CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 26 enrolled
Drug / intervention
gemcitabine hydrochloride +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01535924
NCT01535924Phase 2Completed

A Phase I/II Study Of Gemcitabine And Bendamustine In Patients With Relapsed Or Refractory Hodgkin's Lymphoma

Beth Christian·interventional·Posted Feb 20, 2012·Updated Nov 19, 2021

In Brief

A Phase 2 clinical trial evaluating gemcitabine hydrochloride and bendamustine hydrochloride for Adult Lymphocyte Depletion Hodgkin Lymphoma and 5 related conditions. Completed, enrolled 26 participants across 2 sites.

Detailed Summary

This phase I/II trial studies the side effects and best dose of bendamustine hydrochloride when given together with gemcitabine hydrochloride and to see how well it works in treating patients with relapsed or refractory Hodgkin lymphoma. Drugs used in chemotherapy, such as gemcitabine hydrochloride and bendamustine hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug, combination chemotherapy, may kill more cancer cells.

Study Details

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 20, 2012
Enrollment StartFeb 9, 2012
Primary CompletionFeb 20, 2019
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 14.4 years ago

Interventions

gemcitabine hydrochloridedrug

Given IV

bendamustine hydrochloridedrug

Given IV